Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage i lung cancer patients treated with stereotactic body radiation therapy: A retrospective clinical study

Noriyoshi Takahashi, Takaya Yamamoto, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Rei Umezawa, Yojiro Ishikawa, Maiko Kozumi, Yu Katagiri, Syun Tasaka, Kazuya Takeda, Ken Takeda, Suguru Dobashi, Keiichi Jingu

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

The aim of this study was to determine whether metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are associated with outcomes in Stage I lung cancer patients treated with stereotactic body radiation therapy (SBRT). Thirty-eight patients underwent [18F] fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG-PET/CT) within 60 days before SBRT at our institution between January 2001 and December 2011. The maximum standardized uptake value (SUVmax), MTV2, MTV4, MTV6, TLG40%, TLG50% and TLG60% were calculated. Prognostic factors for overall survival (OS) and local control (LC) were analyzed using Cox's proportional hazards model, and survival curves were calculated using the Kaplan-Meier method. Receiver operating characteristics (ROC) curves of PET parameters for OS and LC were calculated. The median follow-up period for survivors was 37.7 months. Three-year OS and LC rates were 56.4% and 70.5%, respectively, and 5-year OS and LC rates were 36.8% and 70.5%, respectively. In univariate analyses, tumor diameter (P = 0.019), single dose ≥10 Gy (P = 0.017), MTV2 (P = 0.030) and MTV4 (P = 0.048) were significant predictors for OS. Tumor diameter (P < 0.001), single dose ≥10 Gy (P = 0.007), SUVmax (P = 0.035), MTV2 (P < 0.001), MTV4 (P = 0.003), MTV6 (P = 0.017), TLG40% (P < 0.001), TLG50% (P = 0.001) and TLG60% (P = 0.003) were significant predictors for LC. SUVmax was not a significant predictor for OS. We made the ROC curves at PET parameters, and the largest area under the curve value for OS was MTV2 and for LC was TLG40%. Tumor diameter, single dose ≥10 Gy, MTV2 and MTV4 are prognostic factors for OS and LC rates and MTV2 is a better prognostic factor for OS than other PET parameters.

Original languageEnglish
Pages (from-to)655-661
Number of pages7
JournalJournal of radiation research
Volume57
Issue number6
DOIs
Publication statusPublished - 2016 Nov 1

Keywords

  • Metabolic tumor volume
  • NSCLC
  • Non-small cell lung cancer
  • Prognostic factor
  • Stereotactic body radiation therapy
  • Total lesion glycolysis

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage i lung cancer patients treated with stereotactic body radiation therapy: A retrospective clinical study'. Together they form a unique fingerprint.

Cite this